We recently published a list of 10 Firms Battered by Poor Earnings, Dismal Outlook. In this article, we are going to take a look at where Cytokinetics, Inc. (NASDAQ:CYTK) stands against other Friday’s worst performers.

Wall Street’s major indices ended the trading week on a strong note, clocking in robust gains as investors cheered better-than-expected non-farm payrolls last month while digesting more corporate earnings results.

The tech-heavy Nasdaq led the rally among all major indices, finishing up 1.51 percent. The S&P 500 clocked in a 1.47-percent gain, while the Dow Jones grew by 1.39 percent.

Despite the broader market optimism, 10 companies managed to register declines amid dismal earnings performance in the first quarter of the year. In this article, let us explore Friday’s 10 worst performers and the reasons behind their decline.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Why Cytokinetics, Inc. (CYTK) Went Down On Friday?

A lab technician using a microscope to examine the biopharmaceutical company's molecules.

Cytokinetics, Inc. (NASDAQ:CYTK)

Cytokinetics fell by 12.98 percent on Friday to finish at $37.35 apiece as investor sentiment was weighed down by the Food and Drug Administration’s (FDA) decision to delay its approval of the company’s heart treatment.

According to the FDA, it asked Cytokinetics, Inc. (NASDAQ:CYTK) for the risk evaluation and mitigation strategy of aficamten, which pushed back the result of its review to December 26 from the original target date of September. The company said it had already complied with the request.

Aficamten is currently under review as a treatment for obstructive hypertrophic cardiomyopathy, a heart disorder in which cardiac muscle becomes abnormally thick, making it harder for the heart to pump blood.

“We believe the commercial prospects of aficamten are highly dependent on whether FDA approves aficamten with a label and/or post-marketing conditions that are less challenging to prescribers and patients than the REMS applicable to Camzyos, Cytokinetics, Inc. (NASDAQ:CYTK) said in its report.

For his part, Cytokinetics President and CEO Robert Blum said that he “remains confident in the distinct benefit-risk and pharmaceutic profile of aficamten and continues to expect a differentiated label and risk mitigation profile upon its potential approval by the FDA.”

Overall, CYTK ranks 3rd on our list of Friday’s worst performers. While we acknowledge the potential of CYTK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CYTK but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

Story Continues

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments